TJ DaRenTang plans to sell 12% of its shares in Tianjin Shike for 1.623 billion yuan to increase cash inflow
TJ DaRenTang plans to sell its 12% stake in Tianjin Shike Pharmaceutical Co., Ltd. for RMB 1.623 billion to increase cash inflow. In this transaction, TJ DaRenTang will transfer 4.6% equity to Haleon (China) for RMB 622 million and 7.4% equity to Haleon CH SARL for RMB 1.001 billion. After the transaction is completed, TJ DaRenTang will no longer hold shares in Tianjin Shike, and it is expected to impact the company's current investment income by approximately RMB 1.54 billion
According to the Zhitong Finance APP, DRTG (600329.SH) announced that its affiliated company, China-US Tianjin Schering Pharmaceutical Co., Ltd. (referred to as "Tianjin Schering"), is a Sino-foreign joint venture limited liability company. The shareholders consist of the company holding 12% of the shares, Haleon UK Services Limited (referred to as "Haleon UK") holding 55% of the shares, and Haleon (China) Co., Ltd. (referred to as "Haleon China") holding 33% of the shares. Currently, Haleon China and Haleon CH SARL (CHE-102.429.188) (referred to as "Haleon CH SARL") are actively seeking to acquire the 12% equity stake in Tianjin Schering held by the company, with their offer representing a 35% premium over the asset appraisal value. Based on the fact that this transaction is beneficial for increasing the company's cash inflow and aligns with the company's focus on its core business development strategy, the company intends to agree to transfer 4.6% of its equity in Tianjin Schering to Haleon China at a transaction price of 622 million RMB, and to transfer 7.4% of its equity in Tianjin Schering to Haleon CH SARL at a transaction price of 1.001 billion RMB. Upon completion of this transfer, the company will no longer hold any equity in Tianjin Schering. Preliminary estimates indicate that this transaction is expected to impact the company's current investment income by approximately 1.54 billion RMB
